↓ Skip to main content

Cochrane Database of Systematic Reviews

Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Overview of attention for article published in Cochrane database of systematic reviews, December 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
4 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
43 Mendeley
Title
Ursodeoxycholic acid for cystic fibrosis-related liver disease.
Published in
Cochrane database of systematic reviews, December 2014
DOI 10.1002/14651858.cd000222.pub3
Pubmed ID
Authors

Cheng K, Ashby D, Smyth RL, Cheng, Katharine, Ashby, Deborah, Smyth, Rosalind L

Abstract

Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction and abnormal bile flow ultimately results in the development of cystic fibrosis-related liver disease. This condition peaks in adolescence with up to 20% of adolescents with cystic fibrosis developing chronic liver disease. Early changes in the liver may ultimately result in end-stage liver disease with people needing transplantation. One therapeutic option currently used is ursodeoxycholic acid. To analyse evidence that ursodeoxycholic acid improves indices of liver function, reduces the risk of developing chronic liver disease and improves outcomes in general in cystic fibrosis. We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also contacted drug companies.Date of the most recent search of the Group's trials register: 29 May 2014. Randomised controlled trials of the use of ursodeoxycholic acid for at least three months compared with placebo or no additional treatment in people with cystic fibrosis. Two authors independently assessed trial eligibility and quality. Ten trials have been identified, of which three trials involving 118 participants were included; the dose of ursodeoxycholic acid ranged from 10 to 20 mg/kg/day for up to 12 months. The complex design used in two trials meant that data could only be analysed for subsets of participants. There was no significant difference in weight change, mean difference -0.90 kg (95% confidence interval -1.94 to 0.14) based on 30 participants from two trials. Improvement in biliary excretion was reported in only one trial and no significant change after treatment was shown. There were no data available for analysis for long-term outcomes such as death or need for liver transplantation. There are few trials assessing the effectiveness of ursodeoxycholic acid. There is insufficient evidence to justify its routine use in cystic fibrosis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Unknown 42 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 26%
Student > Ph. D. Student 6 14%
Student > Doctoral Student 5 12%
Professor 3 7%
Researcher 3 7%
Other 9 21%
Unknown 6 14%
Readers by discipline Count As %
Medicine and Dentistry 22 51%
Nursing and Health Professions 4 9%
Biochemistry, Genetics and Molecular Biology 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Agricultural and Biological Sciences 2 5%
Other 5 12%
Unknown 5 12%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2017.
All research outputs
#1,640,774
of 22,774,233 outputs
Outputs from Cochrane database of systematic reviews
#3,730
of 12,314 outputs
Outputs of similar age
#24,058
of 354,430 outputs
Outputs of similar age from Cochrane database of systematic reviews
#95
of 278 outputs
Altmetric has tracked 22,774,233 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.4. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,430 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 278 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.